Last updated: February 19, 2026
TREMFYA, a selective IL-23 inhibitor developed by Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson), has established a significant position in the treatment of plaque psoriasis and psoriatic arthritis. Its efficacy in reducing disease activity and improving patient-reported outcomes, coupled with a favorable safety profile, underpins its market penetration and financial performance.
What is TREMFYA's Mechanism of Action and Target Indications?
TREMFYA targets the p19 subunit of interleukin-23 (IL-23). IL-23 is a cytokine that plays a central role in the pathogenesis of inflammatory diseases by promoting the survival and differentiation of T helper 17 (Th17) cells and other immune cells, leading to the production of pro-inflammatory cytokines such as IL-17A, IL-17F, and IL-22.
The primary indications for TREMFYA are:
- Moderate to severe plaque psoriasis: TREMFYA is approved for adult patients with plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Active psoriatic arthritis: TREMFYA is indicated for adult patients with active psoriatic arthritis who have had an inadequate response or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
These indications address significant unmet needs in chronic inflammatory conditions characterized by immune dysregulation.
What are TREMFYA's Key Clinical Efficacy and Safety Data?
Clinical trial data demonstrate TREMFYA's robust efficacy.
In the SC psoriasis indication, pivotal Phase 3 studies, including VOYAGE 1 and VOYAGE 2, showed that TREMFYA achieved high rates of skin clearance. For example, in VOYAGE 1 at week 16, 92% of patients treated with TREMFYA achieved at least a 75% reduction in Psoriasis Area and Severity Index (PASI 75) score, and 65% achieved PASI 90. A significant proportion, 35%, achieved PASI 100 (clear skin) [1]. These results were sustained over extended treatment periods, with over 80% of patients maintaining PASI 75 at week 52 in VOYAGE 1 [1].
For active psoriatic arthritis, the DISCOVER-1 and DISCOVER-2 trials established TREMFYA's efficacy. In DISCOVER-1, at week 24, 52% of patients treated with TREMFYA achieved at least a 20% improvement in American College of Rheumatology (ACR20) criteria, compared to 32% for placebo. Furthermore, 43% achieved minimal disease activity (MDA) [2]. In DISCOVER-2, 64% of patients achieved ACR20 response at week 24, versus 37% for placebo, with 45% achieving MDA [2].
TREMFYA generally exhibits a favorable safety profile. Common adverse events include upper respiratory tract infections, headache, fatigue, and injection site reactions. Serious adverse events are infrequent and include hypersensitivity reactions and infections. The drug is not associated with the boxed warnings for serious infections, malignancy, or cardiovascular events that are seen with some other biologic therapies in this class.
What is the Competitive Landscape for TREMFYA?
TREMFYA competes in the rapidly growing biologic market for inflammatory diseases, primarily against other IL-23 inhibitors, TNF-alpha inhibitors, and IL-17 inhibitors.
Key competitors include:
- IL-23 Inhibitors:
- Skyrizi (risankizumab) (AbbVie): Approved for plaque psoriasis, psoriatic arthritis, and Crohn's disease. Skyrizi is a direct competitor with a similar mechanism of action and dosing frequency.
- Ilumya (tildrakizumab) (Sun Pharma): Approved for moderate to severe plaque psoriasis. Ilumya is also an IL-23 inhibitor with a different dosing schedule.
- IL-17 Inhibitors:
- Cosentyx (secukinumab) (Novartis): Approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Cosentyx is a highly effective IL-17A inhibitor.
- Taltz (ixekizumab) (Eli Lilly and Company): Approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Taltz targets IL-17A.
- Veklury (brodalumab) (Valeant Pharmaceuticals, now Bausch Health): Approved for moderate to severe plaque psoriasis. Brodalumab targets the IL-17 receptor.
- TNF-alpha Inhibitors:
- Humira (adalimumab) (AbbVie): A widely used TNF-alpha inhibitor with broad indications, including psoriasis and psoriatic arthritis.
- Enbrel (etanercept) (Amgen): Another established TNF-alpha inhibitor.
- Remicade (infliximab) (Janssen Biotech/Merck): A chimeric monoclonal antibody targeting TNF-alpha.
- Cimzia (certolizumab pegol) (UCB): A PEGylated anti-TNF biologic.
TREMFYA's differentiation lies in its specific targeting of the IL-23 p19 subunit, which leads to a potent and sustained suppression of IL-23 signaling without affecting IL-12 signaling, potentially contributing to its favorable safety profile. Its infrequent dosing schedule (every eight weeks after initial doses) is also a key competitive advantage for patient adherence.
What is TREMFYA's Market Penetration and Growth Trajectory?
TREMFYA has demonstrated robust market penetration since its launch. Global sales for TREMFYA reached $2.9 billion in 2022 [3]. This represents substantial growth from its initial launch year. The market for biologics in dermatology and rheumatology is expanding due to increasing disease awareness, improved diagnostic capabilities, and the availability of more effective and patient-friendly treatments.
Factors contributing to TREMFYA's growth include:
- Clinical Superiority: High efficacy rates in achieving skin clearance and disease remission.
- Favorable Safety Profile: Lack of significant safety warnings compared to some older biologics.
- Convenient Dosing: Every-eight-week injection schedule enhances patient compliance and quality of life.
- Expanding Indications: Potential for future label expansions into other IL-23-mediated inflammatory diseases.
- Physician and Patient Preference: Growing recognition and prescription volume driven by clinical trial data and real-world evidence.
The market for IL-23 inhibitors, in particular, is projected to continue its upward trend as they offer targeted therapy with a favorable risk-benefit profile. TREMFYA is well-positioned to capture a significant share of this growing market.
What are TREMFYA's Financial Performance and Outlook?
Johnson & Johnson's Pharmaceuticals segment, which includes TREMFYA, has seen significant contributions from the drug.
Annual Net Sales:
- 2020: $1.56 billion [4]
- 2021: $2.20 billion [5]
- 2022: $2.90 billion [3]
This trend indicates an average year-over-year growth rate exceeding 35% in recent years. This performance is driven by increasing prescription volumes and market share gains.
Financial Outlook:
Analysts project continued strong growth for TREMFYA. While specific future sales figures are proprietary, market consensus suggests that TREMFYA will remain a blockbuster drug, exceeding $5 billion in annual sales in the coming years. Key drivers for this outlook include:
- Ongoing Market Expansion: The global market for psoriasis and psoriatic arthritis treatments is projected to grow.
- Lifecycle Management: Johnson & Johnson is likely to explore further indications for TREMFYA.
- Patent Expirations: The patent landscape for TREMFYA needs careful monitoring. While primary patents provide substantial market exclusivity, the timing of biosimilar entry will be critical for long-term revenue. Current patent protections are expected to shield the drug from significant generic competition until the late 2020s or early 2030s, depending on jurisdiction and specific patent challenges.
- Geographic Expansion: Continued rollout and market penetration in emerging markets.
Risks to the financial outlook include increased competition from new entrants or next-generation therapies, pricing pressures from payers, and potential regulatory changes.
What is the Intellectual Property (IP) Landscape for TREMFYA?
TREMFYA is protected by a portfolio of patents covering its composition of matter, methods of use, and manufacturing processes. The primary composition of matter patent is expected to expire in 2031 in the United States, with similar protection likely in other major markets.
Key IP considerations include:
- Composition of Matter Patents: These are the strongest patents, protecting the molecule itself.
- Method of Use Patents: These patents cover specific indications and dosing regimens.
- Formulation Patents: Patents protecting specific drug formulations, which can extend exclusivity.
- Manufacturing Process Patents: Patents related to the methods of producing TREMFYA.
Johnson & Johnson actively defends its intellectual property. Challenges from biosimilar manufacturers are anticipated as the core patent expiry dates approach. The strength and breadth of the patent portfolio, along with ongoing litigation and potential for patent extensions, will dictate the timeline for biosimilar entry and the duration of TREMFYA's market exclusivity.
What are the Key Drivers for Future TREMFYA Growth?
Future growth for TREMFYA will be propelled by several factors:
- Expansion into New Indications: Clinical trials are ongoing for other IL-23-mediated diseases, such as inflammatory bowel disease (IBD - Crohn's disease and ulcerative colitis). Success in these indications could significantly broaden TREMFYA's market.
- Real-World Evidence and Market Adoption: As more physicians and patients gain experience with TREMFYA, its reputation for efficacy and tolerability will likely increase, driving further adoption.
- Combination Therapies: While TREMFYA is typically used as monotherapy, potential for its use in combination with other agents for treatment-resistant patients may emerge, though this is less common for advanced biologics in these indications.
- Emerging Markets: Expanding access and physician education in regions where biologic uptake is still developing.
- Patient Persistence: The convenience of the dosing regimen is a critical factor for long-term patient retention, which directly impacts revenue.
What are the Regulatory Considerations for TREMFYA?
TREMFYA has received approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
- FDA Approval:
- Plaque Psoriasis: December 2017
- Psoriatic Arthritis: December 2017
- EMA Approval:
- Plaque Psoriasis: October 2017
- Psoriatic Arthritis: September 2018
Regulatory oversight continues post-approval, including post-marketing surveillance for safety and efficacy. Any new indications require separate regulatory submissions and approvals. Changes in regulatory pathways for biosimilers could also impact the competitive landscape and market dynamics for TREMFYA.
Key Takeaways
- TREMFYA is a highly effective IL-23 inhibitor for plaque psoriasis and psoriatic arthritis, demonstrating strong clinical efficacy and a favorable safety profile.
- The drug has achieved substantial market penetration, with 2022 sales reaching $2.9 billion and continued strong year-over-year growth.
- TREMFYA faces competition from other IL-23 inhibitors, IL-17 inhibitors, and TNF-alpha inhibitors, but its specific mechanism of action and dosing schedule provide competitive advantages.
- The intellectual property portfolio is robust, with primary composition of matter patents expected to expire around 2031, suggesting a period of market exclusivity extending for several more years.
- Future growth is contingent on potential label expansions into new indications, continued market adoption, and expansion into emerging markets.
Frequently Asked Questions
1. What is the projected revenue for TREMFYA in the next five years?
While precise figures are proprietary, market analysis suggests TREMFYA is on track to surpass $5 billion in annual sales within the next five years, driven by ongoing market penetration and potential indication expansion.
2. When is the earliest a biosimilar version of TREMFYA could enter the U.S. market?
Based on the expiration of key composition of matter patents, the earliest a biosimilar is likely to enter the U.S. market is around 2031, though specific patent litigation and challenges could alter this timeline.
3. Are there ongoing clinical trials for TREMFYA in indications beyond psoriasis and psoriatic arthritis?
Yes, Johnson & Johnson is investigating TREMFYA for other inflammatory diseases, including inflammatory bowel disease (Crohn's disease and ulcerative colitis).
4. How does TREMFYA's dosing frequency compare to its main competitors like Skyrizi and Cosentyx?
TREMFYA is administered subcutaneously every eight weeks after an initial dosing schedule. Skyrizi also follows an every-eight-week regimen after initial doses for psoriasis. Cosentyx has a more frequent initial dosing schedule but can be maintained every four weeks for maintenance therapy in some indications.
5. What is the primary mechanism by which TREMFYA achieves its therapeutic effect?
TREMFYA selectively inhibits the p19 subunit of interleukin-23 (IL-23), a cytokine that plays a critical role in the inflammatory pathways of conditions like psoriasis and psoriatic arthritis by driving the proliferation and activity of pro-inflammatory immune cells.
Citations
[1] Papp, K. A., Blauvelt, A., Warren, R. B., Reich, K., Lebwohl, M., Nast, A., ... & Lj, G. (2017). Phase 3 trials of guselkumab in moderate-to-severe psoriasis. New England Journal of Medicine, 376(17), 1622-1632.
[2] Ritchlin, C. T., Leonardi, C. L., Gladman, D. D., Reich, K., Kavanaugh, A., Blauvelt, A., ... & Lj, G. (2020). Guselkumab in active psoriatic arthritis: efficacy and safety results from the phase 3 DISCOVER-1 trial. The Lancet, 395(10237), 1665-1677.
[3] Johnson & Johnson. (2023). 2022 Annual Report. Retrieved from https://www.sec.gov/ix?doc=/Archives/edgar/data/200406/000020040623000005/jnj-20221231.htm
[4] Johnson & Johnson. (2021). 2020 Annual Report. Retrieved from https://www.sec.gov/Archives/edgar/data/200406/000020040621000014/jnj-20201231.htm
[5] Johnson & Johnson. (2022). 2021 Annual Report. Retrieved from https://www.sec.gov/Archives/edgar/data/200406/000020040622000009/jnj-20211231.htm
